Cel-Sci Gets Taiwan Approval For Trials Of Drug For Head, Neck Cancer
This article was originally published in PharmAsia News
Executive Summary
Austria's Cel-Sci has received approved from Taiwan authorities for clinical trials of a treatment for head and neck cancer